Clinical Analysis of 25 Non-Transplanted Multiple Myeloma Patients Treated with Bortezomib Maintenance.
10.19746/j.cnki.issn.1009-2137.2021.01.021
- Author:
Man SHEN
1
;
Zhong-Xia HUANG
1
;
Jia-Jia ZHANG
1
;
Xin LI
2
Author Information
1. Department of Hematology, West District of Beijing Chaoyang Hospital, Capital Medical University, Beijing Multiple Myeloma Research Center, Beijing 100040, China.
2. Department of Hematology, West District of Beijing Chaoyang Hospital, Capital Medical University, Beijing Multiple Myeloma Research Center, Beijing 100040, China,E-mail: lixin0628@sohu.com.
- Publication Type:Journal Article
- MeSH:
Antineoplastic Combined Chemotherapy Protocols;
Bortezomib/therapeutic use*;
Dexamethasone/therapeutic use*;
Disease-Free Survival;
Humans;
Multiple Myeloma/drug therapy*;
Retrospective Studies;
Treatment Outcome
- From:
Journal of Experimental Hematology
2021;29(1):131-136
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To investigate the efficacy, survival and adverse effects of non-transplanted multiple myeloma (MM) patients treated with bortezomib maintenance.
METHODS:A total of 25 newly diagnosed/relapsed non-transplanted MM patients treated in West District of Beijing Chaoyang Hospital from June 2004 to November 2015 were analyzed retrospectively. All patients received PD regimen (bortezomib and dexamethasone), including bortezomib at a dose of 1.3 mg/m
RESULTS:Till November 1, 2017, 5 patients achieved stringent complete response (sCR), 8 patients achieved complete response (CR), 7 patients achieved very good partial response (VGPR), 4 patients achieved partial reponse (PR), while 1 patient achieved stable disease (SD). After maintenance therapy, 21 patients maintained the efficacy above PR, of which 1 patient was improved from CR to sCR; 4 patients adjusted chemotherapy after disease progressed. Median maintenance therapy was 9 cycles (range from 6 to 31), and the median maintenance time was 27 months (range from 18 to 97). Median follow-up time was 73 months (range from 25 to 171). Median progress-free survival (PFS) time was 30 months (range from 9 to 105) and overall survival (OS) time was 57 months (range from 27 to 160). Till November 1, 2019, 3-year survival rate was 84% (21/25), and 5-year survival rate was 72% (13/18). The most common adverse events were transient leukopenia, thrombocytopenia and peripheral neuropathy, which the patients could tolerate after the prevention and treatment.
CONCLUSION:Bortezomib-based maintenance therapy for non-transplanted MM patients can be an option in consideration of its safety and efficacy.
